SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001683168-23-006528
Filing Date
2023-09-19
Accepted
2023-09-18 19:51:50
Documents
13
Period of Report
2023-09-14
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT cns_8k.htm   iXBRL 8-K 38092
2 2020 EQUITY PLAN (AMENDED AND RESTATED) cns_ex1001.htm EX-10.1 101997
  Complete submission text file 0001683168-23-006528.txt   334434

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE cnsp-20230914.xsd EX-101.SCH 3018
4 XBRL LABEL FILE cnsp-20230914_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE cnsp-20230914_pre.xml EX-101.PRE 22361
7 EXTRACTED XBRL INSTANCE DOCUMENT cns_8k_htm.xml XML 3418
Mailing Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027
Business Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027 1-800-946-9185
CNS Pharmaceuticals, Inc. (Filer) CIK: 0001729427 (see all company filings)

IRS No.: 822318545 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39126 | Film No.: 231262269
SIC: 2834 Pharmaceutical Preparations